HKHelena Käck

Helena Käck

*This is an algorithmically generated author record based on publicly available information.

Helena Käck has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Room-temperature fragment screening of soluble epoxide hydrolase by serial crystallography

    by Andreas Dunge, Gabrielle Wehlander, Gisela Brändén, Helena Käck

    Room temperature serial crystallography offers advantages over conventional cryo-crystallography, such as simplified crystal handling and the possibility to avoid potential artefacts associated with cryo-trapping. However, to be considered as an alternative for drug discovery, where compound availability may be limited and speed of structure delivery is a key factor, it suffers from several limitations. To address these challenges, we have optimized a serial crystallography workflow for ligand soaking, data collection and data processing, significantly reducing time and reagent consumption to make it a viable option for drug discovery applications, herein exemplified by crystallographic fragment screening. Our approach incorporates the use of dried-in fragment cocktails on fixed target supports, compatible with 96-well plates for crystal soaking, and an efficient data processing pipeline tailored for serial crystallography. To validate our workflow, we conducted an in-crystal fragment screen at room temperature on the protein soluble epoxide hydrolase. The screen comprised 384 compounds and resulted in identification of 40 fragment binders corresponding to a hit rate of 10.4 %. The resulting room-temperature structures are of high quality and reveal opportunities for specific interaction within the highly hydrophobic active site of soluble epoxide hydrolase. Finally, we discuss potential avenues for further workflow optimization, highlighting the future potential of this approach for drug discovery. Synopsis: We have developed a workflow that allowed us to efficiently conduct a fragment screen at room temperature using serial crystallography, of interest for future drug discovery campaigns.

  • Protein crystallization strategies in structure-based drug design

    by Margareta Ek, Linda Öster, Helena Käck, Tove Sjögren

    Efficient structure-based design requires robust protocols for generating protein-ligand complex structures to support iterative chemical optimization. However, developing reliable crystallization conditions suitable for drug discovery remains challenging, especially for novel targets and when working with diverse ligand classes. The review focuses on establishing robust crystallization workflows and providing solutions when standard methods prove inadequate for obtaining protein-ligand crystal structures. In addition to reviewing the literature for generic technical advances, the authors provide a comprehensive overview of project- and protein-specific approaches. To further substantiate their claims, the authors analyzed metadata from their proprietary structure collection, representing 20 years of crystallography supporting structure-based drug design. The authors provide two detailed examples showcasing rescue strategies in action. Crystal structures will remain fundamental to structure-based drug design moving forward. Successful crystallization demands adaptable, multi-faceted strategies that systematically explore diverse protein variants and crystallization conditions. Future progress depends on integrating AI tools for construct design with project insights and robust experimental workflows. Success ultimately hinges on synergy between innovative problem-solving approaches and deep expertise in navigating this rapidly evolving landscape.


  • Open Access

    Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction

    by Chunyu Lin, Dilip Narayanan, Marilia Barreca, Cecilie Poulsen, Leandro Silva da Costa, Xiangrong Chen, Kendall G. Wichman, Cherisse A. Charley, Jaslin L. Lindsay, Mahya Dezfouli, et al.

    Activating the cytoprotective response of nuclear factor erythroid 2‐related factor 2 (Nrf2) can reduce oxidative stress and inflammation. A promising strategy is to inhibit the protein‐protein interaction between Kelch‐like ECH‐associated protein 1 (Keap1) and Nrf2 using noncovalent compounds that target the Keap1 Kelch domain. These compounds may be more specific than covalent Keap1‐reacting Nrf2 activators. However, the development of drug‐like noncovalent Keap1‐Nrf2 inhibitors faces challenges due to the size and polarity of the Kelch binding pocket. Here, we present a new series of noncovalent Keap1‐Nrf2 inhibitors developed from a weak fragment hit identified by crystallographic screening. A two‐step growing strategy and optimization guided by several X‐ray cocrystal structures led to compounds with low nanomolar affinities and complete selectivity for Keap1 in a panel of homologous Kelch domains. In cells, compounds 24 and 28 potently activated the expression of Nrf2‐controlled genes and showed anti‐inflammatory effects by downregulating NLRP3 inflammasome and STING signalling activation. RNA sequencing revealed activation of cytoprotective pathways and a different profile from typical covalent Nrf2 activators. This work highlights the potential of fragment‐based drug discovery for challenging targets like Keap1 and introduces novel Keap1‐Nrf2 inhibitors as chemical probes and drug leads.

  • Open Access

    Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction

    by Chunyu Lin, Dilip Narayanan, Marilia Barreca, Cecilie Poulsen, Leandro Silva da Costa, Xiangrong Chen, Kendall G. Wichman, Cherisse A. Charley, Jaslin L. Lindsay, Mahya Dezfouli, et al.

    Activating the cytoprotective response of nuclear factor erythroid 2‐related factor 2 (Nrf2) can reduce oxidative stress and inflammation. A promising strategy is to inhibit the protein‐protein interaction between Kelch‐like ECH‐associated protein 1 (Keap1) and Nrf2 using noncovalent compounds that target the Keap1 Kelch domain. These compounds may be more specific than covalent Keap1‐reacting Nrf2 activators. However, the development of drug‐like noncovalent Keap1‐Nrf2 inhibitors faces challenges due to the size and polarity of the Kelch binding pocket. Here, we present a new series of noncovalent Keap1‐Nrf2 inhibitors developed from a weak fragment hit identified by crystallographic screening. A two‐step growing strategy and optimization guided by several X‐ray cocrystal structures led to compounds with low nanomolar affinities and complete selectivity for Keap1 in a panel of homologous Kelch domains. In cells, compounds 24 and 28 potently activated the expression of Nrf2‐controlled genes and showed anti‐inflammatory effects by downregulating NLRP3 inflammasome and STING signalling activation. RNA sequencing revealed activation of cytoprotective pathways and a different profile from typical covalent Nrf2 activators. This work highlights the potential of fragment‐based drug discovery for challenging targets like Keap1 and introduces novel Keap1‐Nrf2 inhibitors as chemical probes and drug leads.


  • Open Access

    Macromolecular crystallography from an industrial perspective – the impact of synchrotron radiation on structure-based drug discovery

    by H. Käck, T. Sjögren

    Structure-based drug design has been an integral part of drug discovery for over three decades, contributing to the development of numerous approved drugs. Here we discuss the evolution, as well as the current state, of structure-based drug design within the pharmaceutical industry, using data from AstraZeneca's internal repository for crystal structures to provide additional context. Over the past 20 years, the company has transitioned from a mixed in-house and synchrotron data collection model to a `synchrotron-only' approach, enabled by technological advancements at synchrotron facilities. We provide real-world examples of structure delivery to projects, including a high-throughput project and a case where a single structure was pivotal for discovering a candidate drug. We conclude that, despite recent developments in single-particle cryo-EM and deep-learning structure prediction methods, macromolecular crystallography remains a critical tool for drug discovery.


  • Open Access

    Exploring serial crystallography for drug discovery

    by A. Dunge, C. Phan, O. Uwangue, M. Bjelcic, J. Gunnarsson, G. Wehlander, H. Käck, G. Brändén

    Structure-based drug design is highly dependent on the availability of structures of the protein of interest in complex with lead compounds. Ideally, this information can be used to guide the chemical optimization of a compound into a pharmaceutical drug candidate. A limitation of the main structural method used today – conventional X-ray crystallography – is that it only provides structural information about the protein complex in its frozen state. Serial crystallography is a relatively new approach that offers the possibility to study protein structures at room temperature (RT). Here, we explore the use of serial crystallography to determine the structures of the pharmaceutical target, soluble epoxide hydrolase. We introduce a new method to screen for optimal microcrystallization conditions suitable for use in serial crystallography and present a number of RT ligand-bound structures of our target protein. From a comparison between the RT structural data and previously published cryo-temperature structures, we describe an example of a temperature-dependent difference in the ligand-binding mode and observe that flexible loops are better resolved at RT. Finally, we discuss the current limitations and potential future advances of serial crystallography for use within pharmaceutical drug discovery.


  • Open Access

    The structures of salt-inducible kinase 3 in complex with inhibitors reveal determinants for binding and selectivity

    by Linda Öster, Marie Castaldo, Emma de Vries, Fredrik Edfeldt, Nils Pemberton, Euan Gordon, Linda Cederblad, Helena Käck


  • Open Access

    A cell-active cyclic peptide targeting the Nrf2/Keap1 protein–protein interaction

    by Jessica Iegre, Sona Krajcovicova, Anders Gunnarsson, Lisa Wissler, Helena Käck, Anna Luchniak, Stefan Tångefjord, Frank Narjes, David R. Spring

    The disruption of the protein–protein interaction (PPI) between Nrf2 and Keap1 is an attractive strategy to counteract the oxidative stress that characterises a variety of severe diseases. Peptides represent a complementary approach to small molecules for the inhibition of this therapeutically important PPI. However, due to their polar nature and the negative net charge required for binding to Keap1, the peptides reported to date exhibit either mid-micromolar activity or are inactive in cells. Herein, we present a two-component peptide stapling strategy to rapidly access a variety of constrained and functionalised peptides that target the Nrf2/Keap1 PPI. The most promising peptide, P8-H containing a fatty acid tag, binds to Keap1 with nanomolar affinity and is effective at inducing transcription of ARE genes in a human lung epithelial cell line at sub-micromolar concentration. Furthermore, crystallography of the peptide in complex with Keap1 yielded a high resolution X-ray structure, adding to the toolbox of structures available to develop cell-permeable peptidomimetic inhibitors.


  • Open Access

    Combining structural and coevolution information to unveil allosteric sites

    by Giuseppina La Sala, Christopher Pfleger, Helena Käck, Lisa Wissler, Philip Nevin, Kerstin Böhm, Jon Paul Janet, Marianne Schimpl, Christopher J. Stubbs, Marco De Vivo, et al.

    Structure-based three-parameter model that integrates local binding site information, coevolutionary information, and information on dynamic allostery to identify potentially hidden allosteric sites in ensembles of protein structures.


  • Fragment-Based Discovery of Novel Allosteric MEK1 Binders

    by Paolo Di Fruscia, Fredrik Edfeldt, Igor Shamovsky, Gavin W. Collie, Anna Aagaard, Louise Barlind, Ulf Börjesson, Eva L. Hansson, Richard J. Lewis, Magnus K. Nilsson, et al.

    The MEK1 kinase plays a critical role in key cellular processes, and as such, its dysfunction is strongly linked to several human diseases, particularly cancer. MEK1 has consequently received considerable attention as a drug target, and a significant number of small-molecule inhibitors of this kinase have been reported. The majority of these inhibitors target an allosteric pocket proximal to the ATP binding site which has proven to be highly druggable, with four allosteric MEK1 inhibitors approved to date. Despite the significant attention that the MEK1 allosteric site has received, chemotypes which have been shown structurally to bind to this site are limited. With the aim of discovering novel allosteric MEK1 inhibitors using a fragment-based approach, we report here a screening method which resulted in the discovery of multiple allosteric MEK1 binders, one series of which was optimized to sub-μM affinity for MEK1 with promising physicochemical and ADMET properties.